← Back to Search

Patients with Resectable (Cohort B) for Pancreatic Cancer

N/A
Recruiting
Led By Christos Fountilas, MD
Research Sponsored by Roswell Park Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights

Study Summary

To collect samples and information from patients who will be undergoing standard of care neoadjuvant treatment with either FOLFIRINOX or Gemcitabine + Nab-paclitaxel. The information collected will be used to determine if there are any "biomarkers" in your blood or tumor tissue that, when compared to your response to the neoadjuvant treatment, could be used to choose the best treatment option for future patients with similar biomarkers.

Eligible Conditions
  • Pancreatic Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Retrospective prediction of pCR in borderline resectable patients
Retrospective prediction of pCR in resectable patients
Secondary outcome measures
RECIST 1.1 response
Survival status

Trial Design

2Treatment groups
Experimental Treatment
Group I: Patients with Resectable (Cohort B)Experimental Treatment1 Intervention
Pathological response of Patients with resectable disease (per NCCN criteria) treated with standard care chemotherapy
Group II: Patients with Borderline Resectable (Cohort A)Experimental Treatment1 Intervention
Pathological response of Patients with borderline resectable disease (per NCCD Criteria) treated with standard care chemotherapy

Find a Location

Who is running the clinical trial?

Roswell Park Cancer InstituteLead Sponsor
405 Previous Clinical Trials
31,232 Total Patients Enrolled
Christos Fountilas, MDPrincipal InvestigatorRoswell Park Comprehensive Cancer Center
~67 spots leftby Jul 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top